Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of...
Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-[kappa]B and in a PPAR[gamma]-dependent manner
About this item
Full title
Author / Creator
Publisher
Spandidos Publications
Journal title
Language
English
Formats
Publication information
Publisher
Spandidos Publications
Subjects
More information
Scope and Contents
Contents
Rosiglitazone is a synthetic peroxisome proliferator-activated receptor (PPAR)[gamma] agonist widely used for the treatment of type 2 diabetes. Recent studies have demonstrated that rosiglitazone displays anti-inflammatory effects. The present study aimed to investigate whether rosiglitazone alleviates decreases in RAW264.7 cell viability resulting...
Alternative Titles
Full title
Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-[kappa]B and in a PPAR[gamma]-dependent manner
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A669991221
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A669991221
Other Identifiers
ISSN
1792-0981
DOI
10.3892/etm.2021.10175
